Relafen 750, a novel formulation of naproxen, presents a intriguing copyrightple from the biochemical pharmacy view. Its mechanism of action, essentially involving inhibition of cyclooxygenase enzymes – COX-1 and COX-2 – leads to a lowering in prostaglandin synthesis. Considering our biochemical lens, this drug's potency is strongly related to